Description
Humana Press Inc. Therapeutic Lipidology by Michael Davidson
This book is an up-to-date and comprehensive reference on lipidology. It will serve as a stimulus to the reader to continue to learn about the ever changing and fascinating field of therapeutic lipidology. It will also empower readers to improve and extend the lives of the patients they so conscientiously serve._x000D_ _x000D_
Therapeutic Lipidology Table of Contents_x000D_
_x000D_
Chapter 1_x000D_
Lipoprotein Metabolism and Vascular Biology_x000D_
Brian G. Choi, M.D., M.B.A._x000D_
Juan J. Badimon, Ph.D._x000D_
Pedro R. Moreno, M.D._x000D_
Valentin Fuster, M.D., Ph.D._x000D_
Lipoprotein Classification_x000D_
Apolipoprotein Classification_x000D_
Lipid Metabolism_x000D_
HDL Metabolism_x000D_
Lipoprotein Metabolism Regulation_x000D_
Lipids in Vascular Biology and Atherothrombosis_x000D_
_x000D_
Chapter 2_x000D_
Genetic Disorders of Lipoprotein Metabolism_x000D_
Marina Cuchel, M.D., Ph.D._x000D_
Atif Qasim, M.D._x000D_
Daniel J. Rader, M.D._x000D_
Lipid Disorders Involving Elevated Triglycerides_x000D_
Inherited Syndromes of Elevated LDL-Cholesterol_x000D_
Inherited Syndromes of Low LDL-Cholesterol_x000D_
Inherited Syndromes of Low HDL-C_x000D_
Inherited Syndromes of Elevated HDL-C Levels_x000D_
_x000D_
Chapter 3_x000D_
International Guidelines for Dyslipidemia Management_x000D_
Cathleen E. Maki, R.N., M.S.N., N.P._x000D_
The Canadian Guidelines_x000D_
The European Guidelines_x000D_
Joint British Societies Guidelines_x000D_
_x000D_
Chapter 4_x000D_
Pathophysiology and Management of Dyslipidemias Associated with_x000D_
Obesity, Type 2 Diabetes and Other Insulin Resistant States_x000D_
Kevin C. Maki, Ph.D._x000D_
Obesity and Type 2 Diabetes Mellitus_x000D_
Cardiometabolic Risk Syndrome_x000D_
Lipid Abnormalities Associated with Insulin Resistance_x000D_
Functions of Insulin_x000D_
Excessive Production of Very-low Density Lipoproteins (VLDL): The_x000D_
Primary Lipid Abnormality in the Insulin Resistant State_x000D_
Reasons for Elevated Free Fatty Acid Levels in Insulin Resistant States_x000D_
Formation of Small, Dense LDL Particles_x000D_
Mechanisms Linking Insulin Resistance to Low HDL Cholesterol_x000D_
Activities of Lipoprotein and Hepatic Lipases and Their Relationships_x000D_
to Atherogenic Dyslipidemia_x000D_
Lifestyle Management for Atherogenic Dyslipidemia_x000D_
Drug Therapies for Atherogenic Dyslipidemia_x000D_
Intensification of Efforts to Lower LDL-C as a Means of Achieving the_x000D_
Non-HDL-C Goal_x000D_
Targeting Triglyceride-rich Lipoprotein Reduction as a Means of_x000D_
AchievingNon-HDL-C Goal_x000D_
Management of Diabetic Dyslipidemia_x000D_
_x000D_
Chapter 5_x000D_
C-Reactive Protein and Other Inflammatory Markers in Cardiovascular_x000D_
Disease_x000D_
Natalie Khuseyinova, M.D._x000D_
Wolfgang Koenig, M.D., Ph.D._x000D_
C-reactive Protein_x000D_
Cytokines_x000D_
Markers of Hemostasis, that are also Acute Phase Reactants_x000D_
Plasminogen Activator Inhibitor-1_x000D_
D-Dimer_x000D_
Von Willebrand Factor_x000D_
White Blood Cell Count _x000D_
Lipid-related Biomarkers_x000D_
Oxidised (Ox) LDL_x000D_
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)_x000D_
Adiponectin_x000D_
_x000D_
Chapter 6_x000D_
Dietary Prescriptions to Control Dyslipidemias and Coronary Disease Risk_x000D_
Margo A. Denke, M.D._x000D_
A Diet-Enthusiast's Summary of The Evolving Role of Diet_x000D_
Pre-Statin Cholesterol Lowering (1960-1987)_x000D_
Early Statin Years: LDL Lowering (1987-1994)_x000D_
Landmark Statin Trials, LDL Lowering and Eruption of the Metabolic_x000D_
Syndrome (1994-2004)_x000D_
Lipid Therapy Beyond LDL and CHD Prevention Dietary Therapies Beyond_x000D_
Lipids 2004-present_x000D_
_x000D_
Chapter 7_x000D_
Pharmacological Therapy for Cardiovascular Disease: Current and_x000D_
Emerging Therapies_x000D_
Michael H. Davidson, M.D., F.A.C.C., F.A.C.P. _x000D_
Statins_x000D_
Ezetimibe_x000D_
Bile Acid Sequestrants_x000D_
Niacin_x000D_
Fibrates_x000D_
Omega-3 Fatty Acids _x000D_
_x000D_
Chapter 8_x000D_
Effects of Thiazolidinediones on Serum Lipoproteins_x000D_
Anjli Maroo, M.D., R.V.T._x000D_
W. H. Wilson Tang, M.D., F.A.C.C._x000D_
Mechanisms of TZD Actions on Serum Lipoproteins_x000D_
Clinical Evidence of Lipid Lowering Effects of TZDs_x000D_
Meta-Analyses of Pioglitazone and Rosiglitazone Trials_x000D_
Prospective Comparative Clinical Studies_x000D_
Concomitant TZD and Statin Therapy_x000D_
Outcome Studies_x000D_
Future Directions_x000D_
_x000D_
Chapter 9_x000D_
High-Density Lipoproteins_x000D_
Peter P. Toth, M.D., Ph.D._x000D_
Antiatherogenic Effects of HDL_x000D_
Epidemiologic Studies Evaluating the Relationship between HDL and Risk_x000D_
for Cardiovascular Disease_x000D_
The Definition and Prevalence of Low HDL_x000D_
Effects of Lifestyle Modification on HDL_x000D_
Pharmacologic Therapy for Low_x000D_